THE OPPORTUNITY
Below the Roll-Up Line
In New York, 65% of solo ophthalmologists are in the succession window today, while only 22 new solo practices have opened statewide in 5 years. These practices fall below the EBITDA scale institutional capital needs for multiple arbitrage, so PE walked away. The result is a large, fragmented seller base with no buyer built to serve it.
Institutional capital once passed on dental for the same reasons it's passing on ophthalmology today. Ontario Teachers' Pension Plan partnered with Heartland Dental in 2012, and KKR acquired a stake in 2018 at a substantially higher valuation.
Those objections proved irrelevant once Heartland scaled from 397 offices to 840+ under operator management. Ophthalmology sits at the same inflection now: 4,300 solo practices retiring by 2030, still in physician hands, and no consolidator built for it.
Operating Company
These are not failing practices. They are healthy practices running below capacity, where the founder pulled back years before retirement and never replaced the management, so demand still outruns availability. What solo ophthalmology lacked is an operator class built around CPOM, AKS, and fair market value constraints at the scale these practices live. The $4 billion sits in transition because that buyer class never existed.
The Model
Built to Hold, Not to Flip
Verdira acquires practices from retiring physicians and installs a successor who owns the clinical entity, while Verdira operates the MSO that runs everything nonclinical. The MSO earns a fixed monthly fee set at fair market value and locked in dollars, never varying with revenue, volume, or referrals, which keeps it CPOM and AKS compliant by design.
Acquired solo practice
PC · Professional Corporation
The successor physician
Owns the clinical entity and keeps full clinical autonomy.
FIXED MONTHLY MANAGEMENT FEE
FMV · locked in dollars
MSO · Verdira
The operating company
Runs everything non-clinical: facility, equipment, staff, billing, technology, compliance, growth.
CPOM + AKS compliant by design · Permanent hold, no exit clock
Revenue Mechanic
How the MSO Earns Revenue
The Management Fee covers all nonclinical operations: facility, staff, marketing, technology, billing, compliance, and equipment. It is set at fair market value and fixed in dollars, and any structure that pays per procedure or per patient is prohibited under the MSA.
Buy side
How the Fee Compounds
The fee escalates annually under the MSA, so MSO income and platform economics grow with it. The same infrastructure serves each practice added, so the marginal cost of each new acquisition approaches zero.
Why It Holds Through Cycles
Demand That Doesn't Cycle
The model is structurally insulated from the credit and equity cycles that drive private equity healthcare platforms. Three mechanics compound independently of macro sentiment.
01
Federal Demand Backstop
10,000 Boomers turn 65 daily through 2030, and cataract surgery is medically necessary care that patients do not defer during macro uncertainty. The general ophthalmology practices in the pipeline carry significant Medicare payer mix, which functions as a federal payment guarantee.
02
Permanent Hold, No Flip
Verdira holds the platform in perpetuity with no fund liquidation and no exit pressure. An assignment clause in the MSA blocks a PE rollup, the fate of the majority of private equity acquisitions that get resold, so the seller's name, staff, and standing stay intact.
03
Day 1 Operating Cash
Operating cash flow begins on Day 1 of MSA execution and compounds annually with the contractual escalator. The model does not depend on a future exit event for liquidity
Defensibility
The Moat
Five compounding sources of defensibility govern the platform. Each took 12 to 18 months of work and significant capital to build, and a competitor starting today cannot replicate this stack inside 24 months minimum.
Rogue holds 89,666 scored physician records and surfaces 1,698 priority targets across the tristate, resolving each practice's solo status, age, Medicare trajectory, and PE ownership across federal data sets that share no common identifier. A competitor can buy the same raw feeds, but not the resolution logic that took years to build.
02
Regulatory Architecture in the Hardest State
New York is the most restrictive state in the country for healthcare acquisitions, and assembling 200+ pages of agreements compliant with CPOM, AKS, and MSO/PC rules took 18 months of legal engineering. That architecture only grows more valuable as consolidation laws tighten nationally.
CPOM §6530 · MSA Architecture
03
Successor Physician Credentialing
Successor physicians are credentialed by Dr. James Kelly, a top 1% refractive surgeon with more than 100,000 procedures who is aligned on equity under an executed advisory agreement. Replicating that requires a surgeon of his caliber willing to take equity instead of cash.
CAB Chair · Equity Aligned
04
No Competing Buyer for the Segment
These practices sit below institutional private equity thresholds, too small for PE, unviable for hospitals once FMV rules strip out goodwill, and unbankable without collateral. With no peer operator competing for them, Verdira is frequently the seller's only alternative to closing.
Built for the Segment · Flywheel
Track Record
Operators, Not Novices
Verdira is executing its first ophthalmology acquisition. The founding team are operators, not financiers, who have built and run real companies across manufacturing and e-commerce.
Strategic conversations and partnership inquiries are handled by relationship only.